Monument Group Wealth Advisors LLC Makes New $425,000 Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

Monument Group Wealth Advisors LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, HoldingsChannel.com reports. The fund bought 800 shares of the medical research company’s stock, valued at approximately $425,000. Thermo Fisher Scientific accounts for approximately 0.4% of Monument Group Wealth Advisors LLC’s holdings, making the stock its 21st largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in TMO. Sugarloaf Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton lifted its holdings in Thermo Fisher Scientific by 3.7% in the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 19 shares during the period. Tsfg LLC boosted its position in shares of Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after purchasing an additional 19 shares in the last quarter. Pacifica Partners Inc. increased its holdings in shares of Thermo Fisher Scientific by 16.5% in the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 20 shares in the last quarter. Finally, Retirement Planning Group LLC lifted its stake in shares of Thermo Fisher Scientific by 4.9% in the fourth quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 21 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 in the last quarter. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 4.9 %

Shares of TMO opened at $575.10 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a fifty day moving average of $572.03 and a two-hundred day moving average of $528.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The company has a market capitalization of $219.52 billion, a PE ratio of 37.22, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.40 earnings per share. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Evercore ISI raised their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, Citigroup started coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.